{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:54Z","timestamp":1786120314852,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/cmr.0b013e32834d3d88","type":"journal-article","created":{"date-parts":[[2011,11,3]],"date-time":"2011-11-03T03:44:35Z","timestamp":1320291875000},"page":"530-534","source":"Crossref","is-referenced-by-count":97,"title":["Safety and clinical activity of ipilimumab in melanoma patients with brain metastases"],"prefix":"10.1097","volume":"21","author":[{"given":"Jeffrey S.","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Minor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Berman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"O\u2019Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210129","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/107327480901600307","article-title":"Diagnosis and treatment of melanoma brain metastasis: a literature review.","volume":"16","author":"Sloan","year":"2009","journal-title":"Cancer Control"},{"key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system.","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"R3-9-20210129","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ctrv.2004.05.001","article-title":"The treatment of brain metastases in melanoma patients.","volume":"30","author":"Bafaloukos","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"R4-9-20210129","first-page":"2201","article-title":"A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.","volume":"6","author":"McDermott","year":"2000","journal-title":"Clin Cancer Res"},{"key":"R5-9-20210129","first-page":"193","article-title":"Prognostic factors in 1521 melanoma patients with distant metastases.","volume":"181","author":"Barth","year":"1995","journal-title":"J Am Coll Surg"},{"key":"R6-9-20210129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","article-title":"Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma.","volume":"88","author":"Sampson","year":"1998","journal-title":"J Neurosurg"},{"key":"R7-9-20210129","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases.","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"key":"R8-9-20210129","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/cncr.25631","article-title":"Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.","volume":"117","author":"Eigentler","year":"2011","journal-title":"Cancer"},{"key":"R9-9-20210129","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/cncr.25643","article-title":"Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival.","volume":"117","author":"Zakrzewski","year":"2011","journal-title":"Cancer"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.bjc.6605622","article-title":"Determinants of survival in patients with brain metastases from cutaneous melanoma.","volume":"102","author":"Staudt","year":"2010","journal-title":"Br J Cancer"},{"key":"R11-9-20210129","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3171\/2010.5.JNS1014","article-title":"Outcome predictors of gamma knife surgery for melanoma brain metastases: clinical article.","volume":"114","author":"Liew","year":"2011","journal-title":"J Neurosurg"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1586\/14737140.7.12.1699","article-title":"Multimodality management of brain metastases in metastatic melanoma patients.","volume":"7","author":"Samlowski","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-065X.2006.00441.x","article-title":"CNS immune privilege: hiding in plain sight.","volume":"213","author":"Carson","year":"2006","journal-title":"Immunol Rev"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/cncr.22905","article-title":"Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.","volume":"110","author":"Majer","year":"2007","journal-title":"Cancer"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-008-0653-8","article-title":"Ipilimumab: controversies in its development, utility and autoimmune adverse events.","volume":"58","author":"Weber","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","article-title":"Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.","volume":"26","author":"Fong","year":"2008","journal-title":"J Clin Oncol"},{"key":"R18-9-20210129","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory monoclonal antibodies for cancer therapy.","volume":"7","author":"Melero","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"R19-9-20210129","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R20-9-20210129","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.","volume":"21","author":"ODay","year":"2010","journal-title":"Ann Oncol"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncology"},{"key":"R22-9-20210129","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"R23-9-20210129","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R26-9-20210129","first-page":"9","article-title":"Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.","volume":"10","author":"Wolchok","year":"2010","journal-title":"Cancer Immun"},{"key":"R28-9-20210129","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R29-9-20210129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncponc1183","article-title":"CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.","volume":"5","author":"Hodi","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"R30-9-20210129","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/CMR.0b013e3283364a37","article-title":"Complete regression of a previously untreated melanoma brain metastasis with ipilimumab.","volume":"20","author":"Schartz","year":"2010","journal-title":"Melanoma Res"},{"key":"R31-9-20210129","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00008390-201112000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:29:47Z","timestamp":1786048187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00008390-201112000-00009"}},"subtitle":["retrospective analysis of data from a phase 2 trial"],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0b013e32834d3d88","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}